Infarction
Welcome,         Profile    Billing    Logout  
 85 Companies   108 Products   108 Products   99 Mechanisms of Action   9 Trials   2118 News 


«12345678910111213...4041»
  • ||||||||||  Trial completion date, Trial termination:  Nobori And Uncoated Stent In Coronary Attack (clinicaltrials.gov) -  Aug 27, 2018   
    P=N/A,  N=1537, Terminated, 
    Trial completion date: Jul 2017 --> Dec 2017 | Recruiting --> Terminated; Insufficient data collection
  • ||||||||||  Enrollment closed, Enrollment change:  Renal Acute MI Study (clinicaltrials.gov) -  Aug 17, 2018   
    P=N/A,  N=50, Active, not recruiting, 
    Trial completion date: Jul 2017 --> Dec 2017 | Recruiting --> Terminated; Insufficient data collection Recruiting --> Active, not recruiting | N=160 --> 50
  • ||||||||||  Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date:  ST LEUIS: Smartphone Twelve Lead Electrocardiogram Utility In ST-Elevation Myocardial Infarction (clinicaltrials.gov) -  Aug 16, 2018   
    P=N/A,  N=50, Active, not recruiting, 
    Recruiting --> Active, not recruiting | N=160 --> 50 Recruiting --> Active, not recruiting | N=30 --> 50 | Trial completion date: Sep 2017 --> Sep 2018 | Trial primary completion date: Sep 2017 --> Jan 2018
  • ||||||||||  Trial completion, Phase classification, Trial completion date, Trial primary completion date:  STOP-HF: St. Vincent's Screening To Prevent Heart Failure Study (clinicaltrials.gov) -  Jul 27, 2018   
    P=N/A,  N=1378, Completed, 
    Active, not recruiting --> Completed Recruiting --> Completed | Phase classification: P4 --> PN/A | Trial completion date: Jul 2017 --> Dec 2017 | Trial primary completion date: Dec 2012 --> Dec 2017
  • ||||||||||  NN1213 / Novo Nordisk
    Trial primary completion date:  BARDA II: Identify Clinical Conditions That Increase Circulating DNA Levels (clinicaltrials.gov) -  Jul 27, 2018   
    P=N/A,  N=130, Active, not recruiting, 
    Recruiting --> Completed | Phase classification: P4 --> PN/A | Trial completion date: Jul 2017 --> Dec 2017 | Trial primary completion date: Dec 2012 --> Dec 2017 Trial primary completion date: Jul 2018 --> Oct 2018
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion, Trial completion date, Trial primary completion date:  ROMI-3: Optimum Troponin Cutoffs for ACS in the ED (clinicaltrials.gov) -  Jul 26, 2018   
    P=N/A,  N=100, Completed, 
    Trial primary completion date: Jul 2018 --> Oct 2018 Withdrawn --> Completed | Trial completion date: Nov 2016 --> Nov 2017 | Trial primary completion date: Aug 2013 --> Aug 2017
  • ||||||||||  Trial completion, Trial completion date:  CP4ACS: Study to Evaluate the Care Process and the Quality of STEMI Care (clinicaltrials.gov) -  Jul 24, 2018   
    P=N/A,  N=640, Completed, 
    Withdrawn --> Completed | Trial completion date: Nov 2016 --> Nov 2017 | Trial primary completion date: Aug 2013 --> Aug 2017 Enrolling by invitation --> Completed | Trial completion date: Apr 2018 --> Jan 2018
  • ||||||||||  ticagrelor / Generic mfg., aspirin / Generic mfg.
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date:  On-treatment PLAtelet Reactivity-guided Therapy Modification FOR ST-segment Elevation Myocardial Infarction (clinicaltrials.gov) -  Jul 18, 2018   
    P3,  N=242, Terminated, 
    Enrolling by invitation --> Completed | Trial completion date: Apr 2018 --> Jan 2018 N=632 --> 242 | Trial completion date: Oct 2019 --> Jan 2018 | Recruiting --> Terminated | Trial primary completion date: Jun 2019 --> Jan 2018; An interim analysis showed that there is no difference in the primary endpoint, given the small number of events in the groups examined.
  • ||||||||||  clopidogrel / Generic mfg.
    Trial completion:  ARTE: Aspirin Versus Aspirin+Clopidogrel as Antithrombotic Treatment Following TAVI (clinicaltrials.gov) -  Jul 17, 2018   
    P4,  N=222, Completed, 
    N=632 --> 242 | Trial completion date: Oct 2019 --> Jan 2018 | Recruiting --> Terminated | Trial primary completion date: Jun 2019 --> Jan 2018; An interim analysis showed that there is no difference in the primary endpoint, given the small number of events in the groups examined. Active, not recruiting --> Completed
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion:  FUTURE: Functional Testing Underlying Coronary Revascularisation (clinicaltrials.gov) -  Jun 26, 2018   
    P=N/A,  N=941, Completed, 
    N=150 --> 27 | Trial completion date: Jan 2018 --> Jun 2018 | Recruiting --> Terminated | Trial primary completion date: Jan 2018 --> Jun 2018 Active, not recruiting --> Completed
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion, Phase classification:  LIPSIA-COND: Effect of Conditioning on Myocardial Damage in STEMI (clinicaltrials.gov) -  Jun 26, 2018   
    P=N/A,  N=600, Completed, 
    Active, not recruiting --> Completed Recruiting --> Completed | Phase classification: P4 --> PN/A
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion, Trial primary completion date:  Neuroprotective Goal Directed Hemodynamic Optimization in Post-cardiac Arrest Patients (clinicaltrials.gov) -  Jun 26, 2018   
    P=N/A,  N=112, Completed, 
    Recruiting --> Completed | Phase classification: P4 --> PN/A Recruiting --> Completed | Trial primary completion date: Dec 2017 --> Jun 2018
  • ||||||||||  TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
    Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date, Head-to-Head:  DIVA: Superiority of Rt-PA + Tenecteplase in Comparison With Rt-PA Only in Proximal Middle Cerebral Artery Occlusion (clinicaltrials.gov) -  Jun 21, 2018   
    P2,  N=0, Withdrawn, 
    Recruiting --> Completed | Trial primary completion date: Dec 2017 --> Jun 2018 N=60 --> 0 | Trial completion date: Mar 2018 --> Sep 2018 | Not yet recruiting --> Withdrawn | Trial primary completion date: Dec 2017 --> Jul 2018
  • ||||||||||  atorvastatin / Generic mfg.
    Trial completion, Surgery:  STAR-VaS: Statin Drugs to Prevent Complications During Surgery (clinicaltrials.gov) -  Jun 12, 2018   
    P=N/A,  N=60, Completed, 
    N=60 --> 0 | Trial completion date: Mar 2018 --> Sep 2018 | Not yet recruiting --> Withdrawn | Trial primary completion date: Dec 2017 --> Jul 2018 Active, not recruiting --> Completed
  • ||||||||||  nimodipine / Generic mfg.
    Trial completion:  Nimodipine for Treating Acute Massive Cerebral Infarction (clinicaltrials.gov) -  May 1, 2018   
    P4,  N=72, Completed, 
    Recruiting --> Completed | Trial completion date: Mar 2017 --> Jun 2017 | Trial primary completion date: Mar 2017 --> Jun 2017 Recruiting --> Completed
  • ||||||||||  timolol maleate ophthalmic solution / Generic mfg.
    Trial completion date, Trial primary completion date:  Treatment of Port-wine Mark in Sturge-Weber Syndrome Using Topical Timolol (clinicaltrials.gov) -  Apr 25, 2018   
    P1,  N=10, Recruiting, 
    Recruiting --> Completed Trial completion date: Jun 2018 --> Dec 2019 | Trial primary completion date: Dec 2017 --> Dec 2019
  • ||||||||||  Stemedyne-MSC (human bone marrow-derived ischemia tolerant mesenchymal cells) / Stemedica Cell Technologies
    Trial completion date:  A Study of Allogeneic Mesenchymal Bone Marrow Cells in Subjects With Ischemic Stroke (clinicaltrials.gov) -  Apr 18, 2018   
    P1/2,  N=38, Active, not recruiting, 
    Trial completion date: Jun 2018 --> Dec 2019 | Trial primary completion date: Dec 2017 --> Dec 2019 Trial completion date: Dec 2017 --> Dec 2018
  • ||||||||||  Enrollment change, Trial withdrawal, Stroma:  SAMCIS: Mesenchymal Stromal Cells for Ischemic Stroke (clinicaltrials.gov) -  Apr 18, 2018   
    P1/2,  N=0, Withdrawn, 
    Trial completion date: Dec 2017 --> Dec 2018 N=48 --> 0 | Not yet recruiting --> Withdrawn
  • ||||||||||  Trial completion date, Trial primary completion date:  BASIC VALIDATE Coronary Stent Registry (clinicaltrials.gov) -  Apr 11, 2018   
    P=N/A,  N=0, Withdrawn, 
    Recruiting --> Completed Trial completion date: Jul 2021 --> Apr 2018 | Trial primary completion date: Jun 2021 --> Apr 2018
  • ||||||||||  Tysabri (natalizumab) / Biogen, Royalty
    Trial completion, Trial completion date, Trial primary completion date:  ACTION2: Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke (clinicaltrials.gov) -  Apr 9, 2018   
    P2,  N=270, Completed, 
    Recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: Feb 2018 --> Nov 2017 | Trial primary completion date: Feb 2018 --> Nov 2017
  • ||||||||||  Hygroton (chlortalidone) / Alliance, NN1213 / Novo Nordisk
    Phase classification:  Genetics of Hypertension Associated Treatments (GenHAT) (clinicaltrials.gov) -  Apr 6, 2018   
    P,  N=37939, Completed, 
    Active, not recruiting --> Completed | Trial completion date: Feb 2018 --> Nov 2017 | Trial primary completion date: Feb 2018 --> Nov 2017 Phase classification: P=N/A --> P
  • ||||||||||  Resolute ZES (zotarolimus-eluting stent) / Medtronic
    Trial completion, Phase classification, Trial completion date, Real-world evidence, Real-world:  R-C Registry: RESOLUTE China Registry: (clinicaltrials.gov) -  Apr 6, 2018   
    P,  N=1800, Completed, 
    Recruiting --> Completed | Trial primary completion date: Sep 2017 --> Dec 2017 Active, not recruiting --> Completed | Phase classification: PN/A --> P | Trial completion date: Jul 2018 --> Dec 2017
  • ||||||||||  ticagrelor / Generic mfg., clopidogrel / Generic mfg.
    Enrollment change, Trial completion date:  TACAT: Comparing Ticagrelor and Clopidogrel Pharmacodynamics After Thrombolysis (clinicaltrials.gov) -  Apr 4, 2018   
    P4,  N=0, Withdrawn, 
    Active, not recruiting --> Completed | Phase classification: PN/A --> P | Trial completion date: Jul 2018 --> Dec 2017 N=70 --> 0 | Trial completion date: Jul 2016 --> Mar 2018
  • ||||||||||  Enrollment closed, Phase classification, Trial completion date, Trial primary completion date:  Optimizing Patient's Selection for Endovascular Treatment in Acute Ischemic Stroke (clinicaltrials.gov) -  Mar 31, 2018   
    P,  N=500, Active, not recruiting, 
    Recruiting --> Completed Recruiting --> Active, not recruiting | Phase classification: PN/A --> P | Trial completion date: Oct 2018 --> May 2018 | Trial primary completion date: Oct 2018 --> May 2018
  • ||||||||||  Trial completion:  ARISEII: Analysis of Revascularization in Ischemic Stroke With EmboTrap (clinicaltrials.gov) -  Mar 31, 2018   
    P=N/A,  N=228, Completed, 
    Recruiting --> Active, not recruiting | Phase classification: PN/A --> P | Trial completion date: Oct 2018 --> May 2018 | Trial primary completion date: Oct 2018 --> May 2018 Recruiting --> Completed
  • ||||||||||  omeprazole / Generic mfg., dabigatran etexilate / Generic mfg.
    Trial completion, Surgery:  Management of Myocardial Injury After Noncardiac Surgery Trial (clinicaltrials.gov) -  Mar 26, 2018   
    P3,  N=1754, Completed, 
    Active, not recruiting --> Completed Active, not recruiting --> Completed
  • ||||||||||  Enrollment closed, Trial completion date, Trial primary completion date:  CONDI2: Effect of RIC on Clinical Outcomes in STEMI Patients Undergoing pPCI (clinicaltrials.gov) -  Mar 13, 2018   
    P=N/A,  N=2613, Active, not recruiting, 
    N=1900 --> 0 | Suspended --> Withdrawn Recruiting --> Active, not recruiting | Trial completion date: Feb 2019 --> Sep 2019 | Trial primary completion date: Feb 2018 --> Mar 2019